Autopsy report · NCT01533727

CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Few patients would like to participate ,since CIK cell transfusion was a new treatment and its efficacy was doubted.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Sun Yat-sen University
Sponsor type: University, hospital or other
Conditions: Non-small Cell Lung Cancer
Interventions: Autologous CIK Transfusion plus Chemotherapy; chemotherapy alone
Participants: 0
Sites: 1
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.